PepGen Inc.
PEPGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, PepGen Inc. focuses on Biotechnology services and products. PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The $146.6M market capitalization puts PEPG squarely in micro-cap range for its industry. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Market Cap
$146.6M
Beta
1.88
P/E (TTM)
—
P/E (Fwd)
-1.72
EPS (TTM)
$-1.41
EPS (Fwd)
$-1.23
ROE
-68.4%
ROA
-35.8%
Cash
$132.3M
Total Debt
$16.6M
Free CF
-$49.8M
52W Change
51.4%
Annual Financials
Cash vs Debt
Where PEPG stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, PEPG finished 35.28% below its 150-day moving average ($3.77) and 40.05% below its 200-day moving average ($4.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PEPG overbought or oversold?
At the July 15, 2026 close, PEPG's RSI(14) was 78.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $132.3M in cash comfortably exceeding the $16.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$49.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -68.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, PEPG tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, PEPG has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PEPG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.